Yoshitaka Tatematsu, Takahiro Imaizumi, Nobuaki Michihata, Noritoshi Kato, Ryosuke Kumazawa, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Shoichi Maruyama. Annual trends in atypical haemolytic uremic syndrome management in Japan and factors influencing early diagnosis and treatment: a retrospective study. Scientific Reports. 2024. 14. 1
Kosuke Osawa, Shuto Yamamoto, Yukiko Yamano, Ayako Kita, Kota Okamoto, Noritoshi Kato, Yoshitaka Tatematsu, Fumiyoshi Kojima, Masaki Ohya, Shigeo Hara, et al. Overlapping Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy with Mutation in <i>CFI</i> in a Japanese Patient: A Case Report. Internal Medicine. 2024. 63. 12. 1777-1782
Daijo Inaguma, Yoshitaka Tatematsu, Naoki Okamoto, Soshiro Ogata, Hideki Kawai, Eiichi Watanabe, Yukio Yuzawa, Midori Hasegawa, Naotake Tsuboi. Multicentre, open-label, randomised, controlled trial to compare early intervention with calcimimetics and conventional therapy in preventing coronary artery calcification in patients with secondary hyperparathyroidism (UPCOMING): a study protocol. BMJ Open. 2024. 14. 1. e076962-e076962
Sawako Kato, Yachiyo Kuwatsuka, Masahiko Ando, Yoshitaka Tatematsu, Nobuhiro Nishibori, Shoichi Maruyama. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study). BMC Nephrology. 2023. 24. 1
Yuji Sasakawa, Yoshitaka Tatematsu, Joichiro Kato, Maya Fujii, Naoki Okamoto, Daijo Inaguma. Relationship between serum sodium level at dialysis initiation and all-cause mortality. Clinical and Experimental Nephrology. 2023. 27. 9. 747-756
